Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001128918.3(MARK3):c.113G>A(p.Arg38Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000694 in 1,613,846 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
MARK3 (HGNC:6897): (microtubule affinity regulating kinase 3) The protein encoded by this gene is activated by phosphorylation and in turn is involved in the phosphorylation of tau proteins MAP2 and MAP4. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The c.113G>A (p.R38Q) alteration is located in exon 2 (coding exon 2) of the MARK3 gene. This alteration results from a G to A substitution at nucleotide position 113, causing the arginine (R) at amino acid position 38 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);Gain of catalytic residue at R34 (P = 0.0117);.;